Ajith Karayil, MD
Family Medicine · Bronx, NYNPI 1104011618
Payments from drug & device makers
Across 583 payments — averaging $26.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$3K
- Novo Nordisk$3K
- AstraZeneca$2K
- GSK$2K
- Merck$1K
- Lilly USA, LLC$689
- plus $4K from 27 others
What the payments were for
- Food & beverage$15,737100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 82 | $3,377 |
| Novo Nordisk | 95 | $2,976 |
| AstraZeneca | 87 | $1,694 |
| GSK | 52 | $1,554 |
| Merck | 60 | $1,150 |
| Lilly USA, LLC | 29 | $689 |
| Sanofi-aventis U.S. LLC | 29 | $492 |
| Johnson & Johnson | 11 | $417 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 24 | $415 |
| Amarin Pharma, Inc. | 6 | $290 |
| Otsuka America Pharmaceutical, Inc. | 2 | $266 |
| AbbVie(2 entities) | 8 | $250 |
| Abbott | 12 | $243 |
| Bayer | 10 | $235 |
| Corcept Therapeutics | 7 | $229 |
| Novartis | 11 | $204 |
| Mylan Specialty L.p. | 9 | $181 |
| Exact Sciences | 9 | $148 |
| Pfizer | 6 | $139 |
| Teva Pharmaceuticals USA, Inc. | 8 | $138 |
| Avanir Pharmaceuticals, Inc. | 2 | $126 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| Amgen(2 entities) | 7 | $120 |
| Vifor Pharma, Inc. | 4 | $68 |
| Melinta Therapeutics, LLC | 1 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $34 |
| Gilead | 2 | $30 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Mannkind Corporation | 1 | $20 |
| Radius Health, Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,737 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 296 | $226,822 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 325 | $207,568 |
| JanuviaSitagliptin Phosphate | 209 | $169,757 |
| TradjentaLinagliptin | 186 | $139,000 |
| OzempicSemaglutide | 152 | $138,218 |
| FarxigaDapagliflozin Propanediol | 150 | $109,474 |
| EliquisApixaban | 151 | $99,217 |
| EntrestoSacubitril/Valsartan | 129 | $92,624 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 104 | $67,048 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 127 | $32,058 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 928 | $31,870 |
| LinzessLinaclotide | 42 | $29,240 |
| RybelsusSemaglutide | 15 | $29,090 |
| XareltoRivaroxaban | 21 | $26,088 |
| JanumetSitagliptin Phos/Metformin Hcl | 34 | $25,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $3,377 | $365,822482 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $1,554 | $213,837342 claims |
| MerckJanuvia, Janumet | $1,150 | $195,443243 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $1,694 | $194,613318 claims |
| Novo NordiskOzempic, Rybelsus | $2,976 | $167,308167 claims |
| PfizerEliquis | $139 | $99,217151 claims |
| NovartisEntresto | $204 | $92,624129 claims |
| AbbVieLinzess | $250 | $29,24042 claims |
| Johnson & JohnsonXarelto | $417 | $26,08821 claims |
| Lilly USA, LLCTrulicity | $689 | $24,97925 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $492 | $10,00512 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $5,58713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.
Other family medicine in Bronx
- Eugene SchiffBronx$184K
- Hui-Li HuangBronx$41K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.